Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-04-09
2008-12-09
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S026800
Reexamination Certificate
active
07462605
ABSTRACT:
This invention provides compounds, compositions and methods for treating cancer, infectious disease, an autoimmune disorder or an inflammatory condition. Therapeutic compounds useful in the methods of this invention are 5′-phosphoramidatyl, 1,5-substituted pyrimidine compounds, derivatives, analogs and pharmaceutically acceptable salts thereof.
REFERENCES:
patent: 3852266 (1974-12-01), Kiyanagi et al.
patent: 4247544 (1981-01-01), Bergstrom et al.
patent: 4267171 (1981-05-01), Bergstrom et al.
patent: 4542210 (1985-09-01), Sakata et al.
patent: 4668777 (1987-05-01), Caruthers et al.
patent: 4816570 (1989-03-01), Farquhar
patent: 4948882 (1990-08-01), Ruth
patent: 4963263 (1990-10-01), Kauvar
patent: 4963533 (1990-10-01), De Clercq et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5070082 (1991-12-01), Murdock et al.
patent: 5077282 (1991-12-01), Murdock et al.
patent: 5077283 (1991-12-01), Murdock et al.
patent: 5085983 (1992-02-01), Scanlon
patent: 5116822 (1992-05-01), De Clercq et al.
patent: 5116827 (1992-05-01), Murdock et al.
patent: 5133866 (1992-07-01), Kauver
patent: 5137724 (1992-08-01), Balzarini et al.
patent: 5212161 (1993-05-01), Moriniere et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5217869 (1993-06-01), Kauver
patent: 5233031 (1993-08-01), Borch et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5274162 (1993-12-01), Glazier
patent: 5300425 (1994-04-01), Kauver
patent: 5338659 (1994-08-01), Kauver et al.
patent: 5430148 (1995-07-01), Webber et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5457187 (1995-10-01), Gmeiner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5502037 (1996-03-01), Kondratyev
patent: 5516631 (1996-05-01), Frisch
patent: 5521161 (1996-05-01), Malley et al.
patent: 5527900 (1996-06-01), Balzarini et al.
patent: 5556942 (1996-09-01), Kauvar et al.
patent: 5596018 (1997-01-01), Baba et al.
patent: 5616564 (1997-04-01), Rapaport et al.
patent: 5627165 (1997-05-01), Glazier
patent: 5643893 (1997-07-01), Benson et al.
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5663321 (1997-09-01), Gmeiner et al.
patent: 5733896 (1998-03-01), Holy et al.
patent: 5798340 (1998-08-01), Bischofberger et al.
patent: 5968910 (1999-10-01), Balzarini
patent: 5981507 (1999-11-01), Josephson et al.
patent: 6057305 (2000-05-01), Holy et al.
patent: 6245750 (2001-06-01), Shepard
patent: 6339151 (2002-01-01), Shepard et al.
patent: 6495553 (2002-12-01), Shepard
patent: 6589941 (2003-07-01), Fahrig et al.
patent: 6599499 (2003-07-01), Rosen et al.
patent: 6677314 (2004-01-01), Klecker et al.
patent: 6677315 (2004-01-01), Klecker et al.
patent: 6682715 (2004-01-01), Klecker et al.
patent: 6683045 (2004-01-01), Klecker et al.
patent: 6683061 (2004-01-01), Shepard et al.
patent: 6703374 (2004-03-01), Klecker et al.
patent: 7138388 (2006-11-01), Shepard
patent: 2001/0016329 (2001-08-01), Shepard
patent: 2001/0034440 (2001-10-01), Shepard et al.
patent: 2002/0022001 (2002-02-01), Klecker et al.
patent: 2002/0034473 (2002-03-01), Klecker et al.
patent: 2002/0119094 (2002-08-01), Klecker et al.
patent: 2002/0147175 (2002-10-01), Shepard et al.
patent: 2002/0151519 (2002-10-01), Shepard et al.
patent: 2002/0165199 (2002-11-01), Klecker et al.
patent: 2003/0049201 (2003-03-01), Klecker et al.
patent: 2003/0095921 (2003-05-01), Klecker et al.
patent: 32 29 169 (1984-02-01), None
patent: 0 095 294 (1983-11-01), None
patent: 0 283 065 (1988-09-01), None
patent: 0 311 107 (1989-04-01), None
patent: 0 311 108 (1989-04-01), None
patent: 0 316 592 (1989-05-01), None
patent: 982 776 (1965-02-01), None
patent: 982776 (1965-02-01), None
patent: 88451 (1986-01-01), None
patent: WO 89/05817 (1989-06-01), None
patent: WO 90/03978 (1990-04-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 92/19767 (1992-11-01), None
patent: WO 92/20344 (1992-11-01), None
patent: WO 94/03467 (1994-02-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 94/22483 (1994-10-01), None
patent: WO 95/01806 (1995-01-01), None
patent: WO 95/08556 (1995-03-01), None
patent: WO 95/08558 (1995-03-01), None
patent: WO 95/09865 (1995-04-01), None
patent: WO 95/12678 (1995-05-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO 96/03151 (1996-02-01), None
patent: WO 96/07431 (1996-03-01), None
patent: WO 96/07413 (1996-04-01), None
patent: WO 96/10030 (1996-04-01), None
patent: WO 96/10300 (1996-04-01), None
patent: WO 96/29338 (1996-06-01), None
patent: WO 96/23506 (1996-08-01), None
patent: WO 96/33168 (1996-10-01), None
patent: WO 96/40088 (1996-12-01), None
patent: WO 96/40706 (1996-12-01), None
patent: WO 96/40708 (1996-12-01), None
patent: WO 96/40739 (1996-12-01), None
patent: WO 97/25342 (1997-07-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 97/28179 (1997-08-01), None
patent: WO 97/49717 (1997-12-01), None
patent: WO 98/49177 (1998-11-01), None
patent: WO 99/06072 (1999-02-01), None
patent: WO 99/08110 (1999-02-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 99/20741 (1999-04-01), None
patent: WO 99/23104 (1999-05-01), None
patent: WO 99/37753 (1999-07-01), None
patent: WO 00/18755 (2000-04-01), None
patent: WO 00/33888 (2000-06-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO 01/07454 (2001-02-01), None
patent: WO 01/83501 (2001-11-01), None
patent: WO 01/85749 (2001-11-01), None
patent: WO 2005/012327 (2005-02-01), None
Firestone et al., “A Comparison of the Effects of Antitumor Agents Upon Normal Human Epidermal Keratinocytes and Human Squamous Cell Carcinoma,”Journal of Investigative Dermatology, 94(5), 657-661 (May 1990).
Dagle et al., “Targeted Degradation of mRNA inXenopusoocytes and Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis,”Nucleic Acids Research, 18(16), 4751-4757 (Aug. 25, 1990).
Hakimelahi et al., “Design, Synthesis, and Structure-Activity Relationship of Novel Dinucleotide Analogs as Agents Against Herpes and Human Immunodeficiency Viruses,”Journal of Medicinal Chemistry, 38(23), 4648-4659 (Nov. 10, 1995).
Naesens et al., “Anti-HIV Activity and Metabolism of Phosphoramidate Dericatives of D4T-MP with Variations in the Amino Acid Moiety,” Poster Session 1,The Tenth International Conference on Antiviral Research, Hotel Nikko, Atlanta, GA, Apr. 6-11, 1997; published inAntiviral Research, 34(2), p. A54 (Abstract 40), (Apr. 1997).
Evrard et al., “An in vitro Nucleoside Analog Screening Method for Cancer Gene Therapy,”Cell Biology and Toxicology, 12, 345-350 (1996).
Berkow et al. (eds.),The Merck Manual of Diagnosis and Therapy, 16th Ed., Merck & Co., Rahway, NJ, May 1992, only page 1278 supplied.
Morrison & Boyd (eds.),Organic Chemistry, Allyn & Bacon, Inc., Boston, MA, 1973, onlyh pp. 1170-1180 supplied.
L. B. Townsend (ed.),Chemistry of Nucleosides and Nucleotides, vol. 3, Plenum Press, New York, NY, 1974, only Table of Contents, Bibliograhy pp. 529-535, and Index pp. 537-552 supplied.
The American Heritage College Dictionary, Third Edition, Houghton Mifflin Co., New York, NY, 1997, only p. 668 supplied.
Smith et al., “Second Passage Human Breast Cancer Cells,”Cancer Research, 50(10), 2943-2948 (May 1990).
(RA) Smith et al., “Second Passage Human Breast Cancer Cells,” Cancer Research, 50(10), 2943-2948 (May 1990).
(RA) Smith et al., “Second Passage Human Breast Cancer Cells,” □□Cancer Research, 50(10), 2943-2948 (May 1990).
Abraham et al., “Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2′-deoxyuridine and 1-β-arabinofuranosylcytosine: Evidence of phosphoramidase activity”J. Med. Chem.39:4569-4575 (1996).
Akdas et al., “Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder”Eur. Urol.29:483-486 (1996).
Almasan et al. “Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis”PN
Lehsten Danielle M.
Shepard H. Michael
Vaino Andrew Rein
Celmed Oncology (USA), Inc.
Crane Lawrence E.
Foley & Lardner LLP
Jiang Shaojia Anna
Konski Antoinette F.
LandOfFree
Phosphoramidate compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphoramidate compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoramidate compounds and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039249